hero image
Webinar

Clinical implementation of a meningitis/encephalitis syndromic panel

in a UK hospital

On-demand
icon_0085_cc_gen_calendar-s
Sep 26, 2023
icon_0310_cc_gen_timeinterval-s
60 minutes

About this webinar

Meningitis and encephalitis are life threatening conditions that require prompt treatment. Successful outcomes rely upon early diagnosis of the condition, identification of the specific causative organism and targeted treatment. Historically, routine diagnostics involved microscopy and culture of cerebrospinal fluid (CSF), with culture taking at least 48 hours.

Molecular methods enable clinicians to quickly identify the causative organism, leading to improved patient outcomes. QIAstat-Dx Meningitis/Encephalitis (ME) Panel is a fast multiplex PCR panel that identifies 15 bacterial, viral and fungal targets in CSF. It has the potential to reduce turnaround times for CSF samples, with a processing time of around 2 minutes and a run time of ~1 hour. Our evaluation of the assay’s performance against current methods demonstrated 100% agreement. A total 35 CSF samples were included in the evaluation, 22 from children and 13 from adults. Of these, 15 samples tested positive with QIAstat-Dx ME Panel, detecting Enterovirus (8), VZV (2), Human Parechovirus (1), HSV2 (1), HHV6 (1), Streptococcus pyogenes (1) and Neisseria meningitidis (1).

QIAstat-Dx ME Panel has a clinical impact in the pediatric population, significantly reducing time to result and duration of acyclovir treatment. Other potential benefits being investigated include impact on the length of stay and duration of antimicrobials.

We find QIAstat-Dx ME Panel provides a fast, easy-to-use molecular test that can aid in the management of patients with meningitis and encephalitis.

Speakers

Fill out the form to take part in the event